Additional file 2 of Differences in oxylipin profile in psoriasis versus psoriatic arthritis

Additional file 2: Supplementary Table 1. Characteristics of PsO patients with low (PASI ≤ 2.5) and high (PASI > 2.5) skin disease activity. Supplementary Table 2. Comparison of oxylipins between PsO patients with low (PASI ≤ 2.5) and high (PASI > 2.5) skin disease activity. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 3. Correlation of oxylipins with PASI in PsO patients. The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 4. Correlation of oxylipins with BMI in PsA patients. The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 5. Characteristics of PsA patients with low (PASI ≤ 2.5) and high (PASI > 2.5) skin disease activity. Supplementary Table 6. Comparison of oxylipins in PsA patients with high (PASI > 2.5) versus low (PASI ≤ 2.5) skin disease activity. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 7. Correlation of oxylipins with PASI in PsA patients. The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 8. Comparison of oxylipins in patients with high (PASI > 2.5) versus low (PASI ≤ 2.5) skin disease activity (both cohorts combined). The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 9. Correlation of oxylipins with mNAPSI (both cohorts combined). The correlation coefficients for each oxylipin are presented, along with the significance level. Significant correlations are marked in red. Supplementary Table 10. Comparison of oxylipins between patients with cDAPSA < 13 and patients with cDAPSA > 13. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 11. Comparison of oxylipins between PsA patients with cDAPSA < 27 and patients with cDAPSA < 27. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 12. Characteristics of PsA patients with enthesitis versus PsA patients without enthesitis. Supplementary Table 13. Comparison of oxylipins in PsA patients with enthesitis versus PsA patients without enthesitis. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 14. Comparison of oxylipins in PsO patients with enthesitis versus PsO patients without enthesitis. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 15. Comparison of oxylipins in patients with enthesitis versus patients without enthesitis (both cohorts combined). The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red. Supplementary Table 16. Characteristics of PsO patients with enthesitis versus PsA patients without enthesitis. Supplementary Table 17. Comparison of oxylipins in PsO versus PsA patients. The average value for each oxylipin is presented, along with the significance of the comparison. Significantly different oxylipins are marked in red.